MBIO Mustang Bio Inc.

+2.98  (+112%)
Previous Close 2.66
Open 7.98
Price To Book 4.37
Market Cap 159721963
Shares 28,319,497
Volume 37,520,840
Short Ratio
Av. Daily Volume 58,577

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
CD20 Technology
Relapsed or refractory B-cell non-Hodgkin lymphomas
Phase 1 ongoing with Phase 1/2 trial to be initiated 2019.
Acute myeloid leukemia
Phase 1 trial recruiting.
Phase 1 trial initiation announced October 30, 2018.
CAR-T therapy
HER2-positive breast cancer
Phase 1/2 trial ongoing. Initial data noted in NEJM.
X-linked Severe Combined Immunodeficiency (XSCID)

Latest News

  1. Mustang Bio News: MBIO Stock Skyrockets on New ‘Bubble Boy’ Therapy
  2. Why Mustang Bio Stock Is On Fire Today
  3.  ‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement
  4. The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio
  5. Mustang Bio's stock soars to near 4-fold gain after deal to commercialize 'bubble boy' disease treatment
  6. Behind the licensing deal for St. Jude's 'bubble boy' disease cure
  7. Stocks to watch: Unilever, Moneysupermarket, Mustang Bio, Indivior
  8. St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine
  9. St. Jude develops cure for ‘bubble boy’ disease
  10. Mustang Bio to Present at the World Orphan Drug Congress USA 2019
  11. Mustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance
  12. Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
  13. Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference
  14. Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
  15. Need To Know: Mustang Bio, Inc. (NASDAQ:MBIO) Insiders Have Been Buying Shares
  16. Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
  17. MBIO: Mustang: A Steed on the Fast Track
  18. Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
  19. Investor Expectations to Drive Momentum within Lawson Products, Kingold Jewelry, Liberty Broadband, Mustang Bio, Artesian Resources, and MYnd Analytics — Discovering Underlying Factors of Influence
  20. Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights